The most commonly prescribed GLP1 injectable medications in Australia include: Tirzepatide (brand name: Mounjaro KwikPen), which is a dual GIP/GLP1 receptor agonist supplied as a multi-dose pre-filled pen containing four weekly doses per pen
ARB=angiotensin receptor blocker
Custom values become necessary when working with non-standard vial sizes, specific concentration targets, or when you need precise control over the final solution strength
Other common side effects include: Dizziness and lightheadedness, particularly during the first few weeks Fatigue and low energy , often related to reduced caloric intake Headaches , which typically resolve within the first month Sulfur burps , a distinctive and common complaint Diarrhea , which usually resolves as the body adjusts Injection site reactions including redness and mild swelling Less common but important considerations Some patients experience hair loss on GLP-1 medications
This rate may be even faster as we age, especially after the age of 60 years
These findings led to the strategic development of a unimolecular GLP-1/GCG co-agonist that exploits the energy expenditure and lipolytic properties of GCG and the appetite-suppressing and insulinotropic properties of GLP-1 [6]
